The US Senate's vote on the House's version of the FDA Reauthorization Act (FDARA) without any amendments was preceded – and enabled – by the quick and easy passage of three pharmaceutical-related bills, including controversial right-to-try legislation that was substantially toned down from its original version.
Had the Senate approved the three bills as amendments to the House's version of FDARA, the amended user fee reauthorization...






